MRTX - Mirati submits European marketing application for mutated lung cancer treatment adagrasib

Mirati Therapeutics (NASDAQ:MRTX) on Thursday said it had submitted a marketing application to the European Union's drug regulator for its investigational inhibitor adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) with a certain mutation who have got a least one prior therapy. The application is specifically for adagrasib for the treatment of patients with previously-treated NSCLC with the KRAS G12C mutation. MRTX's submission to the European Medicines Agency follows the U.S. FDA's acceptance in February of the adagrasib new drug application for the same indication. The FDA had set a date of up to Dec. 14 to consider and decide on the application. MRTI stock earlier closed +3.4% at $59.61. It has lost nearly 60% YTD.

For further details see:

Mirati submits European marketing application for mutated lung cancer treatment adagrasib